廣告
香港股市 將在 7 小時 18 分鐘 開市

  • 恒指

    16,385.87
    +134.03 (+0.82%)
     

  • 國指

    5,803.86
    +54.17 (+0.94%)
     

  • 上證綜指

    3,074.22
    +2.84 (+0.09%)
     

  • 道指

    37,694.46
    -58.85 (-0.16%)
     

  • 標普 500

    5,004.45
    -17.76 (-0.35%)
     

  • 納指

    15,597.17
    -86.20 (-0.55%)
     

  • Vix指數

    18.10
    -0.11 (-0.60%)
     

  • 富時100

    7,877.05
    +29.06 (+0.37%)
     

  • 紐約期油

    82.84
    +0.15 (+0.18%)
     

  • 金價

    2,398.90
    +10.50 (+0.44%)
     

  • 美元

    7.8314
    +0.0013 (+0.02%)
     

  • 人民幣

    0.9238
    -0.0001 (-0.01%)
     

  • 日圓

    0.0504
    -0.0001 (-0.20%)
     

  • 歐元

    8.3367
    -0.0194 (-0.23%)
     

  • Bitcoin

    62,686.12
    +1,046.39 (+1.70%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Metacrine Posts Data From MET409 Combination Trial In Diabetes, NASH Patients

Vandana Singh
·1 分鐘文章

  • Metacrine Inc (NASDAQ: MTCR) reported topline results from its Phase 2a trial of MET409 in combination with Eli Lilly And Co's (NYSE: LLY) Jardiance (empagliflozin) in type 2 diabetes and non-alcoholic steatohepatitis (NASH).

  • LDL-cholesterol increases with MET409 were consistent with previous studies and were comparable alone or in combination with empagliflozin.

  • Secondary assessment of liver fat content at 12 weeks indicated a reduction in liver fat in both monotherapy arms and demonstrated additive effects in the combination regimen.

  • All regimens had favorable safety profiles and were generally well-tolerated, with no treatment-related serious adverse events (AEs).

  • Mild-moderate pruritus was reported in 0%-6% of patients across all groups. No pruritus-related treatment discontinuations occurred in any of the cohorts.

  • Price Action: MTCR shares are up 1.06% at $1.43 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.